Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to extend the use of Tacrolimus and Sirolimus to determine how
effective it is in preventing graft versus host disease (GVHD)in patients that have received
non-myeloablative peripheral blood stem cell transplantation.